2009-01-12 16:06:00 -
NeoPharm, Inc. (NASDAQ: NEOL) announced today that it will participate in the OneMedPlace Finance forum in San Francisco, CA from January 13-14, 2009. Laurence P. Birch, President and CEO of NeoPharm, will present on Tuesday, January 13th at 9:30 a.m. Pacific Time, at the Sir Francis Drake Hotel at 450 Powell St.
The Company, based in Lake Bluff,
Illinois, is a publicly traded biopharmaceutical company dedicated to the research, development and commercialization of new and innovative cancer and other drugs for therapeutic applications. The Company's drug development program includes two proprietary platforms:
- Tumor-targeting toxin platform, which includes development for a new indication of Idiopathic Pulmonary Fibrosis
- NeoLipid® drug delivery system
NeoPharm currently has multiple drug candidates in various points of clinical development, including a Phase II trial for LEP-ETU, its liposomal formulation of the widely used cancer drug, paclitaxel, approved and sold in the U.S. as Taxol®. Additionally, its novel, proprietary liposomal delivery system of docetaxel, the active ingredient of Taxotere®, which is used for the treatment of metastatic solid tumors, LE-DT is currently in undergoing a Phase I trial.
Additional information about the Company can be obtained by visiting NeoPharm's web site at www.neopharm.com.
NeoPharm, Inc.
Laurence P. Birch
President & CEO
847-887-0800
lbirch@neopharm.com 
